Summary

Pediatric Health Care Products and Services Market – Scope of Report
TMR’s report on the global pediatric health care products and services market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pediatric health care products and services market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pediatric health care products and services market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pediatric health care products and services market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pediatric health care products and services market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pediatric health care products and services market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pediatric health care products and services market.

The report delves into the competitive landscape of the global pediatric health care products and services market. Key players operating in the global pediatric health care products and services market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pediatric health care products and services market profiled in this report.

Key Questions Answered in Global pediatric health care products and services Market Report
• What is the sales/revenue generated by pediatric health care products and services across all regions during the forecast period?
• What are the opportunities in the global pediatric health care products and services market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Pediatric Health Care Products and Services Market – Research Objectives and Research Approach
The comprehensive report on the global pediatric health care products and services market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pediatric health care products and services market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pediatric health care products and services market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pediatric Health Care Products and Services Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pediatric Health Care Products and Services Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Disease/Disorder/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Disease/Disorder
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease/Disorder, 2023–2031
6.3.1. Allergy and Respiratory
6.3.2. Cancer
6.3.3. Cardiovascular
6.3.4. Central Nervous System
6.3.5. Gastrointestinal
6.3.6. Hormonal Imbalance
6.3.7. Infections
6.3.8. Others
6.4. Market Attractiveness, by Disease/Disorder
7. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2023–2031
7.3.1. Antibiotics
7.3.2. Analgesics
7.3.3. Anti-asthmatics
7.3.4. Antidepressants
7.3.5. Antidiarrheal
7.3.6. Antifungal
7.3.7. Anti-histamines
7.3.8. Antihypertensives
7.3.9. Anti-metabolites
7.3.10. Anti-neoplastic Antibiotics
7.3.11. Antipsychotics
7.3.12. Others
7.3.13. Market Attractiveness, by Drug Class
8. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Service
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Service, 2023–2031
8.3.1. Child Psychiatry Services
8.3.2. Gastrointestinal Services
8.3.3. Pediatric Cancer Services
8.3.4. Pediatric Diabetes Services
8.3.5. Pediatric Heart Services
8.3.6. Others
8.4. Market Attractiveness, by Service
9. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Pediatric Health Care Products and Services Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Disease/Disorder, 2023–2031
10.2.1. Allergy and Respiratory
10.2.2. Cancer
10.2.3. Cardiovascular
10.2.4. Central Nervous System
10.2.5. Gastrointestinal
10.2.6. Hormonal Imbalance
10.2.7. Infections
10.2.8. Others
10.3. Market Attractiveness, by Disease/Disorder
10.4. Market Value Forecast, by Drug Class, 2023–2031
10.4.1. Antibiotics
10.4.2. Analgesics
10.4.3. Anti-asthmatics
10.4.4. Antidepressants
10.4.5. Antidiarrheal
10.4.6. Antifungal
10.4.7. Anti-histamines
10.4.8. Antihypertensives
10.4.9. Anti-metabolites
10.4.10. Anti-neoplastic Antibiotics
10.4.11. Antipsychotics
10.4.12. Others
10.5. Market Attractiveness, by Drug Class
10.6. Market Value Forecast, by Service, 2023–2031
10.6.1. Child Psychiatry Services
10.6.2. Gastrointestinal Services
10.6.3. Pediatric Cancer Services
10.6.4. Pediatric Diabetes Services
10.6.5. Pediatric Heart Services
10.6.6. Others
10.7. Market Attractiveness, by Service
10.8. Market Value Forecast, by Country, 2023–2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Disease/Disorder
10.9.2. By Drug Class
10.9.3. By Service
10.9.4. By Country
11. Europe Pediatric Health Care Products and Services Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease/Disorder, 2023–2031
11.2.1. Allergy and Respiratory
11.2.2. Cancer
11.2.3. Cardiovascular
11.2.4. Central Nervous System
11.2.5. Gastrointestinal
11.2.6. Hormonal Imbalance
11.2.7. Infections
11.2.8. Others
11.3. Market Attractiveness, by Disease/Disorder
11.4. Market Value Forecast, by Drug Class, 2023–2031
11.4.1. Antibiotics
11.4.2. Analgesics
11.4.3. Anti-asthmatics
11.4.4. Antidepressants
11.4.5. Antidiarrheal
11.4.6. Antifungal
11.4.7. Anti-histamines
11.4.8. Antihypertensives
11.4.9. Anti-metabolites
11.4.10. Anti-neoplastic Antibiotics
11.4.11. Antipsychotics
11.4.12. Others
11.5. Market Attractiveness, by Drug Class
11.6. Market Value Forecast, by Service, 2023–2031
11.6.1. Child Psychiatry Services
11.6.2. Gastrointestinal Services
11.6.3. Pediatric Cancer Services
11.6.4. Pediatric Diabetes Services
11.6.5. Pediatric Heart Services
11.6.6. Others
11.7. Market Attractiveness, by Service
11.8. Market Value Forecast, by Country/Sub-region, 2023–2031
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Disease/Disorder
11.9.2. By Drug Class
11.9.3. By Service
11.9.4. By Country/Sub-region
12. Asia Pacific Pediatric Health Care Products and Services Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease/Disorder, 2023–2031
12.2.1. Allergy and Respiratory
12.2.2. Cancer
12.2.3. Cardiovascular
12.2.4. Central Nervous System
12.2.5. Gastrointestinal
12.2.6. Hormonal Imbalance
12.2.7. Infections
12.2.8. Others
12.3. Market Attractiveness, by Disease/Disorder
12.4. Market Value Forecast, by Drug Class, 2023–2031
12.4.1. Antibiotics
12.4.2. Analgesics
12.4.3. Anti-asthmatics
12.4.4. Antidepressants
12.4.5. Antidiarrheal
12.4.6. Antifungal
12.4.7. Anti-histamines
12.4.8. Antihypertensives
12.4.9. Anti-metabolites
12.4.10. Anti-neoplastic Antibiotics
12.4.11. Antipsychotics
12.4.12. Others
12.5. Market Attractiveness, by Drug Class
12.6. Market Value Forecast, by Service, 2023–2031
12.6.1. Child Psychiatry Services
12.6.2. Gastrointestinal Services
12.6.3. Pediatric Cancer Services
12.6.4. Pediatric Diabetes Services
12.6.5. Pediatric Heart Services
12.6.6. Others
12.7. Market Attractiveness, by Service
12.8. Market Value Forecast, by Country/Sub-region, 2023–2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Disease/Disorder
12.9.2. By Drug Class
12.9.3. By Service
12.9.4. By Country/Sub-region
13. Latin America Pediatric Health Care Products and Services Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease/Disorder, 2023–2031
13.2.1. Allergy and Respiratory
13.2.2. Cancer
13.2.3. Cardiovascular
13.2.4. Central Nervous System
13.2.5. Gastrointestinal
13.2.6. Hormonal Imbalance
13.2.7. Infections
13.2.8. Others
13.3. Market Attractiveness, by Disease/Disorder
13.4. Market Value Forecast, by Drug Class, 2023–2031
13.4.1. Antibiotics
13.4.2. Analgesics
13.4.3. Anti-asthmatics
13.4.4. Antidepressants
13.4.5. Antidiarrheal
13.4.6. Antifungal
13.4.7. Anti-histamines
13.4.8. Antihypertensives
13.4.9. Anti-metabolites
13.4.10. Anti-neoplastic Antibiotics
13.4.11. Antipsychotics
13.4.12. Others
13.5. Market Attractiveness, by Drug Class
13.6. Market Value Forecast, by Service, 2023–2031
13.6.1. Child Psychiatry Services
13.6.2. Gastrointestinal Services
13.6.3. Pediatric Cancer Services
13.6.4. Pediatric Diabetes Services
13.6.5. Pediatric Heart Services
13.6.6. Others
13.7. Market Attractiveness, by Service
13.8. Market Value Forecast, by Country/Sub-region, 2023–2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Disease/Disorder
13.9.2. By Drug Class
13.9.3. By Service
13.9.4. By Country/Sub-region
14. Middle East & Africa Pediatric Health Care Products and Services Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease/Disorder, 2023–2031
14.2.1. Allergy and Respiratory
14.2.2. Cancer
14.2.3. Cardiovascular
14.2.4. Central Nervous System
14.2.5. Gastrointestinal
14.2.6. Hormonal Imbalance
14.2.7. Infections
14.2.8. Others
14.3. Market Attractiveness, by Disease/Disorder
14.4. Market Value Forecast, by Drug Class, 2023–2031
14.4.1. Antibiotics
14.4.2. Analgesics
14.4.3. Anti-asthmatics
14.4.4. Antidepressants
14.4.5. Antidiarrheal
14.4.6. Antifungal
14.4.7. Anti-histamines
14.4.8. Antihypertensives
14.4.9. Anti-metabolites
14.4.10. Anti-neoplastic Antibiotics
14.4.11. Antipsychotics
14.4.12. Others
14.5. Market Attractiveness, by Drug Class
14.6. Market Value Forecast, by Service, 2023–2031
14.6.1. Child Psychiatry Services
14.6.2. Gastrointestinal Services
14.6.3. Pediatric Cancer Services
14.6.4. Pediatric Diabetes Services
14.6.5. Pediatric Heart Services
14.6.6. Others
14.7. Market Attractiveness, by Service
14.8. Market Value Forecast, by Country/Sub-region, 2023–2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Disease/Disorder
14.9.2. By Drug Class
14.9.3. By Service
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AstraZeneca plc
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Disease/Disorder Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Boehringer Ingelheim GmbH
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Disease/Disorder Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Eisai Co., Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Disease/Disorder Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Gilead Sciences, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Disease/Disorder Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. GlaxoSmithKline plc
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Disease/Disorder Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Merck & Co., Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Disease/Disorder Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Mylan N.V.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Disease/Disorder Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Novartis AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Disease/Disorder Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Pediapharm, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Disease/Disorder Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Pfizer, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Disease/Disorder Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Sanofi S.A.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Disease/Disorder Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview